Articles related to CLINICAL STUDY

Data from the open label Evaluation of NMDA Modulation for Depressive Episodes (EVOLVE) study presented at Psych Congress 2022 showed a significant decrease in HAM-A scores at 1 week, with further decreases in scores observed through 12 months.

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.

Folic acid (B9) prescription in a population of more than 800,000 individuals, yielded a suicide event rate of 4.73 per 100 000 person-months, compared with a rate of 10.61 per 100 000 person-months without folic acid.

Nearly 20,000 mother-child pairs were tracked over a median follow-up of 4 years. After adjusting for maternal risk factors and their children’s own ultra-processed food intake, physical activity, and sedentary time, maternal consumption of ultra-processed foods during the child-rearing period was associated with overweight or obesity in offspring with a 26% higher risk in the group with the highest maternal ultra-processed food consumption.

This case-control study carried out at six hospitals between Oct 2021 and July 2022 found that boosters yielded a 75% reduction in COVID hospitalization risk in the first 50 days post-booster, declining to 25% reduction in hospitalization risk at over 150 days. Other factors associated with an increased odds of hospitalization for COVID-19 included age of 70 years or older, male sex, cognitive disease, COPD, diabetes, immunodeficiency, obesity, rheumatologic disease, transplant, and Pfizer-BioNTech vaccination.